Pramipexole DihydrochlorideThird Party Manufacturing in India

Pramipexole Dihydrochloride is a synthetic non-ergoline dopamine agonist that binds with high selectivity and full intrinsic activity to dopamine D₂ receptor subfamily members, demonstrating highest affinity for the D₃ receptor subtype followed by D₂ and D₄ receptors. Unlike levodopa, which requires metabolic conversion and depends on residual dopaminergic neuron function, pramipexole directly stimulates postsynaptic dopamine receptors in the striatum, providing therapeutic benefit independent of the progressive degeneration of nigrostriatal dopaminergic neurons. The drug binds to the orthosteric binding site of the D₂-like receptors, inducing a conformational change that activates the Gi/Go protein-coupled signaling cascade, leading to inhibition of adenylyl cyclase, reduction of intracellular cyclic AMP levels, and modulation of ion channel activity. The preferential affinity for D₃ receptors, which are concentrated in the limbic system and ventral striatum, may contribute to its effects on both motor symptoms and mood. Pramipexole also demonstrates neuroprotective properties in preclinical models through multiple mechanisms including reduced oxidative stress, inhibition of mitochondrial permeability transition pore opening, and upregulation of anti-apoptotic proteins such as Bcl-2. Additionally, pramipexole suppresses endogenous dopamine synthesis and turnover via activation of presynaptic autoreceptors, which reduces the oxidative burden from dopamine metabolism in surviving neurons. The drug provides symptomatic control of both early and advanced Parkinson disease while potentially slowing disease progression through these ancillary neuroprotective actions.

Therapeutic Uses

Pramipexole Dihydrochloride is prescribed for neurological conditions involving dopamine deficiency:

• Parkinson Disease: Used as monotherapy in early-stage Parkinson disease to control bradykinesia, rigidity, tremor, and postural instability. In advanced disease, it is used as adjunctive therapy with levodopa to reduce off-time and allow levodopa dose reduction.
• Restless Legs Syndrome: Pramipexole is FDA-approved for moderate-to-severe primary restless legs syndrome, reducing the unpleasant sensations and urge to move that worsen during rest and at night.
• Parkinson Disease Psychosis: Emerging evidence supports the role of pramipexole in managing certain non-motor symptoms of Parkinson disease, though this remains an off-label indication in most markets.

Pramipexole is available in immediate-release tablets for three-times-daily dosing and prolonged-release tablets for once-daily administration. The availability of multiple strengths allows for gradual dose titration to achieve optimal therapeutic response while minimizing side effects.

Why Manufacturers Choose Pramipexole Dihydrochloride

Pramipexole is one of the most prescribed non-ergoline dopamine agonists globally, included in international guidelines as first-line treatment for Parkinson disease motor symptoms. The molecule has multiple strengths across both IR and PR formulations, allowing manufacturers to offer comprehensive titration packs and maintenance therapy options. The growing geriatric population in India and increasing prevalence of Parkinson disease create expanding demand. Pramipexole Dihydrochloride has well-established DMF filings and API supply chains from both domestic and international sources. Indian WHO-GMP manufacturers produce pramipexole for domestic PCD franchise networks, hospital tenders, and regulated market exports. The PR formulation provides a significant value-add opportunity for manufacturers with extended-release tablet technology capabilities.

⚠️ NOTE: Raw data mentioned 1.15mg strength which is unusual. Standard strengths include 1mg and 1.5mg. The 1.15mg strength has been included as per raw data but verification of commercial availability is recommended.